CoChat

A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.

Juric, Dejan, Soria, Jean-Charles, Sharma, Sunil, Banerji, Udai, Azaro, Analia, Desai, Jayesh, Ringeisen, Francois Philippe, Kaag, Audrey, Radhakrishnan, Rajkumar, Hourcade-Potelleret, Florence, Maacke, Heiko, Rodon Ahnert, Jordi · 2014 · Journal of Clinical Oncology
Cited by 55

The DOI matches its Crossref record.

Abstract

9051 Background: The MAPK and PI3K pathways share common upstream activators and contribute to cell proliferation, differentiation, and survival. Due to compensatory signaling, only partial tumor growth inhibition may occur when targeting either pathway alone. Preclinically-observed synergistic effects of combined PI3K and MEK inhibitors suggest that dual inhibition may be more effective. Methods: This phase 1b, open-label study (CMEK162X2109) is evaluating the PI3Kα inhibitor BYL719 combined with MEK inhibitor binimetinib (MEK162) in patients (pts) with RAS- or BRAF-mutant advanced solid malignancies (> 10 types). The objective for dose escalation was estimation of the maximum-tolerated dose (MTD) and/or recommended dose for expansion (RDE), guided by the Bayesian logistic regression model. Results: As of September 2, 2013, 58 pts were enrolled and BYL719 was orally co-administered at 80, 120, 160, 200, 220, or 270 mg once-daily (QD) with binimetinib at 30 or 45 mg twice-daily (BID) in 28-day cycles. Thirty two pts (55%) had ≥3 prior anticancer regimens. Median exposure was 7.4 wks. Common adverse events (AEs), regardless of study drug relationship, were diarrhea (86%), nausea (66%), vomiting (52%), reduced appetite (50%), rash (48%), pyrexia (41%), fatigue (38%), and hyperglycemia (36%). Grade 3/4 AEs occurred in 46 individual pts (79%), most commonly diarrhea (12%) and elevated creatine phosphokinase (10%). Dose-limiting toxicities were observed in 9 pts (19%), out of which 4 had grade 3/4 AEs including gastrointestinal and skin disorders. The MTD of the combination was determined to be BYL719 200 mg QD plus binimetinib 45 mg BID, at which 3/6 pts had grade 3/4 AEs. Of 4 ovarian cancer pts with KRAS-mutant status, 3 had confirmed partial responses (PRs). PRs were also observed in 1 pt with NRAS-mutant melanoma (confirmed) and 1 with KRAS-mutant endometrial cancer (unconfirmed). Stable disease lasting > 6 weeks was reported as best response for 18 pts (31%). Conclusions: The MTD/RDE for combined BYL719 and binimetinib was reached, and the preliminary safety and efficacy profile justifies further exploration, particularly in pts with RAS-mutant ovarian cancer. Clinical trial information: NCT01449058.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.9051

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 55

Metadata

Authors
Juric, D., Soria, J.-C., Sharma, S., Banerji, U., Azaro, A., Desai, J., Ringeisen, F. P., Kaag, A., Radhakrishnan, R., Hourcade-Potelleret, F., Maacke, H., & Rodon Ahnert, J.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
9051-9051
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2604107344
Cited by
55
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.9051
The paper
Juric, D., Soria, J.-C., Sharma, S., Banerji, U., Azaro, A., Desai, J., Ringeisen, F. P., Kaag, A., Radhakrishnan, R., Hourcade-Potelleret, F., Maacke, H., & Rodon Ahnert, J. (2014). A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.9051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.